Last reviewed · How we verify
Consolidation durvalumab
At a glance
| Generic name | Consolidation durvalumab |
|---|---|
| Also known as | IMFINZI, Chemoradiotherapy, Surgery |
| Sponsor | Rachel Sanborn |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. (PHASE3)
- A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy (PHASE2)
- A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (PHASE3)
- BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) (PHASE2)
- Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Consolidation durvalumab CI brief — competitive landscape report
- Consolidation durvalumab updates RSS · CI watch RSS
- Rachel Sanborn portfolio CI